小程序掃碼下單
本網(wǎng)站銷售的所有產(chǎn)品僅用于工業(yè)應(yīng)用或者科學(xué)研究等非醫(yī)療目的，不可用于人類或動(dòng)物的臨床診斷或者治療，非藥用，非食用。
Obinutuzumab
英文名：Obinutuzumab
Cas號(hào)：
Cas號(hào)：
檢測信息查詢
| 貨號(hào) | 規(guī)格 | 貨期 | 庫存 | 價(jià)格 | 促銷價(jià) | 訂購 |
| 1308132497-1mg | 0 | ￥6600 | ||||
| 1308132497-5mg | 0 | ￥16200 |
| 別 名 | |
| Cas號(hào) | |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產(chǎn)品參數(shù) | Description
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. Shipping Shipping with dry ice. Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. [2]. Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85. [3]. Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. |
| 性狀 | Obinutuzumab (GA101) 是新型糖工程化II型CD20單克隆抗體，開發(fā)用來治療非霍奇金淋巴瘤。 |
| 貯存 |
- 優(yōu)特克諾 815610-63-0
- 雷莫蘆單抗 947687-13-0
- Human IgG1 Control
- Abatacept 332348-12-6
- Obinutuzumab
- Reslizumab 241473-69-8
- 那他珠單抗 189261-10-7
- BENRALIZUMAB 1044511-01-4
- Dupilumab 1190264-60-8
滬公網(wǎng)安備 31012002003054號(hào)